Attached files

file filename
EX-99.1 - PRESS RELEASE - Clinigence Holdings, Inc.exhibit991.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 26, 2016

iGambit Inc.

(Exact name of registrant as specified in its charter)

Delaware

000-53862

(State or other jurisdiction

(Commission File Number)

(IRS Employer

of incorporation)

Identification No.)

1050 W. Jericho Turnpike, Suite A

11787

Smithtown, New York

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (631) 670-6777

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of

the registrant under any of the following provisions (see General Instruction A.2. below):

¨    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




ITEM 8.01      Other Events

On  August  22,  2016  iGambit  Inc.   (the  ‘Company”),  entered  into  a  Letter  of  Intent  (the  “LOI”)

with  HubCentrix  Inc.,  a  web-based  collaboration  and  digital  asset  management  company  with  a

special  expertise  in  streamlining  the  process  of  capturing  and  managing  information  in  the

document-intensive medical field.

Pursuant  to  the  LOI,  at  closing, iGambit  Inc.  (“iGambit”)  will  acquire  substantially all  the  assets

of  HubCentrix    Inc.  (“HubCentrix”)  and  will  assume  certain  specifically  identified  operating

liabilities  of  HubCentrix.  Payment  for  the  acquisition  will  be  made  in  the  form  of  five  million

(5,000,000) shares of iGambit common stock.

The LOI has certain binding and non-binding obligations and the transaction is subject to various

conditions   to   closing,   including   satisfactory   completion   of   due   diligence,   approval   of   the

Company’s   Board   of   Directors,   approval   of   the   Company’s   shareholders,   if   required,   and

definitive  documentation.   There  can  be  no  assurance  that  the  transactions  contemplated  by  the

LOI  will  be  consummated.  The  LOI  and  this  Current  Report  on  Form  8-K  do  not  constitute  an

offer to buy, or solicitation of an offer to sell, any securities of the Company and no offer or sale

of such securities will be made in any jurisdiction where it would be unlawful to do so.

ITEM 7.01      Regulation FD Disclosure

On August 26, 2016, the Company issued a press release announcing the LOI, a copy of which is

attached hereto as Exhibit 99.1.

ITEM 9.01 Financial Statements and Exhibits

(d)     Exhibits

The following Exhibits are filed as part of this Report:

99.1     Press Release related to Announcement of Letter of Intent dated August 26, 2016.

Forward–Looking Statements

This   report   regarding   the   Company’s   business   and   operations   includes   “forward-looking

statements”  within  the  meaning  of  the  Private  Securities  Litigation  Reform  Act  of  1996.  Such

statements  consist  of any statement  other than  a  recitation  of historical  fact  and  can  be  identified

by  the  use  of  forward-looking  terminology  such  as  “may,”  “expect,”  “anticipate,”  “intend”  or

“estimate”  or  the  negative  thereof  or  other  variations  thereof  or  comparable  terminology.  The

reader is cautioned that all forward-looking statements are speculative, and there are certain risks

and uncertainties  that  could  cause  actual  events  or results  to  differ from those  referred  to  in  such

forward-looking statements.  This  disclosure  highlights  some  of  the  important  risks  regarding the

Company’s  business.  The  primary  risk  attributable  to  the  Company  is  its  ability  to  attract  fresh

and  continued  capital  to  execute  its  comprehensive  business  strategy.  There  may  be  additional

risks  associated  with  the  integration  of  businesses  following  an  acquisition,  concentration  of

revenue   from   one   source,   competitors   with   broader   product   lines   and   greater   resources,




emergence  into  new  markets,  the  termination  of  any  of  the  Company’s  significant  contracts  or

partnerships,  the  Company’s  ability  to  comply  with  its  senior  debt  agreements,  the  Company’s

inability  to  maintain  working  capital  requirements  to  fund  future  operations,  or  the  Company’s

ability  to  attract  and  retain  highly  qualified  management,  technical  and  sales  personnel, and  the

other factors identified by us from time to time in the Company’s filings with the SEC. However,

the   risks   included   should   not   be   assumed   to   be   the   only   things   that   could   affect   future

performance.  We  may  also  be  subject  to  disruptions,  delays  in  collections,  or  facilities  closures

caused by potential or actual acts of terrorism or government security concerns.

All  forward-looking  statements  included  in  this  document  are  made  as  of  the  date  hereof,  based

on  information  available  to  us  as  of  the  date  thereof,  and  we  assume  no  obligation  to  update  any

forward-looking statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this

report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date:  August 26, 2016

iGambit Inc.

By:

/s/  Elisa Luqman

Elisa Luqman

Chief Financial Officer



Exhibit Index

Exhibit No.     Description

99.1     Press Release related to Announcement of Letter of Intent dated August 26, 2016.

1